We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure [email protected]
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
So far, the book has explored different problems in the life cycle of a vaccine. First, it surveyed the pathways to bring new vaccines to market against a backdrop of lacking incentives to R&D, in spite of the recognized public health value of vaccines and the widespread use of intellectual property rights as an incentive to vaccine R&D. Second, it examined the allocative disparities that result from the commodification of vaccines, especially in situations of product scarcity, in which lower-income populations often face considerable hurdles in obtaining access to vaccines. This section examines possible solutions to alleviate these problems. It considers proposals that would take effect at the incentives level, by increasing funding for vaccine-related R&D work; proposals that would operate at transactional level, facilitating the transfer of vaccine technology through the use of patent pools and patent pledges; and proposals to expand and fine-tune the role of vaccine-dedicated public–private partnerships as instruments for the promotion of equitable access to vaccines by populations irrespective of their socioeconomic status.
This chapter considers the research, development, and implementation of solar geoengineering by nonstate actors and their governance by intellectual property policies. Although some observers are concerned that nonstate actors could deploy it, states will probably retain control over operational decision-making regarding large-scale outdoor tests and implementation. At the same time, commercial entities will play roles – most likely as contractors in public procurement – as providers and innovators of goods and services for solar geoengineering activities. A leading means through which states govern nonstate actors in innovative domains is policies for intellectual property, particularly patents. This chapter reviews the current landscape of patents related to solar geoengineering and the social challenges that such intellectual property could pose. It comments on others’ proposals for intellectual property policies specific to solar geoengineering and also recommends one. Importantly, the suggested "research commons," which is centered on a system of patent pledges, does not require state action and could arise bottom-up among researchers and other nonstate actors.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.